Illinois lawmakers advanced legislation that would create a state board empowered to cap prescription drug prices, one of the most aggressive state-level efforts to control pharmaceutical costs.
The proposed Prescription Drug Affordability Board would review prices for essential medicines and set upper payment limits for insurers, pharmacies, and wholesalers. Supporters said the measure targets manufacturers whose list prices far exceed production costs.
Pharmaceutical industry groups oppose the bill, arguing it could reduce investment in new therapies and faces federal preemption challenges. Constitutional scholars said drugmakers are likely to sue if the board exercises broad pricing authority.
Colorado and Maryland have established similar boards with mixed early results. Illinois advocates pointed to insulin and asthma medication costs as immediate priorities. The bill awaits further votes in the legislative session ending this spring.
The board would review medicines deemed essential for public health and compare U.S. prices to benchmarks in Canada and Europe. Manufacturers have challenged Colorado’s affordability board in court with mixed results. Illinois Governor JB Pritzker has not said whether he will sign the bill if it reaches his desk. Patient advocacy groups support the measure while pharmacy benefit managers remain opposed.
Hospital associations said price caps could disrupt formulary negotiations with insurers. The Illinois bill includes public hearings before setting upper payment limits for selected drugs. Similar legislation in Oregon faced court challenges from pharmaceutical trade groups last year.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://dailycuratednews.substack.com/p/news-headlines-may-22-2026